Paclitaxel 化学構造
分子量: 853.91

高品質保証

カスタマーフィードバック(2)

Quality Control & MSDS

製品説明

  • Compare Microtubule Associated Inhibitors
    Microtubule Associated製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 パクリタキセル(タキソール、Onxol、Nov-Onxol)は、人間の内皮細胞の0.1pMのIC50による微小管ポリマー安定剤です。
ターゲット Microtubule (human endothelial cells)
IC50 0.1 pM [1]
In vitro試験 Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
TE-15 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXBTWM2OD1yLkCwNFI5PyEQvF2= MluwV2FPT0WU
LC-2-ad M3vPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS3VI9bUUN3ME2wMlAxODNzNzFOwG0> NES5N5dUSU6JRWK=
RL95-2 Mmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfPcpBKSzVyPUCuNFAxPjZ6IN88US=> MmmyV2FPT0WU
MZ1-PC NH\ne4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvucnVJUUN3ME2wMlAxODd{OTFOwG0> NUPQ[lg3W0GQR1XS
TE-8 NFrOSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;2TWM2OD1yLkCwNVE4KM7:TR?= NELoRXFUSU6JRWK=
SW954 NH32XZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\rd3FKSzVyPUCuNFAyOTlizszN MYPTRW5ITVJ?
TE-11 M4HKSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMECxNlMh|ryP NIjmSWVUSU6JRWK=
PSN1 NYjzSXJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33zVmlEPTB;MD6wNFE{KM7:TR?= MXzTRW5ITVJ?
MOLT-4 M2\jO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMECxOFkh|ryP M{LUV3NCVkeHUh?=
697 NXf4dW5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLWTWM2OD1yLkCwNVUh|ryP NHTDb5hUSU6JRWK=
ETK-1 MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rlcGlEPTB;MD6wNFE2OiEQvF2= M1nyb3NCVkeHUh?=
TE-10 NE\CZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXGTWM2OD1yLkCwNVU1KM7:TR?= Mn\SV2FPT0WU
HUTU-80 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfjeIw3UUN3ME2wMlAxOTZ6IN88US=> NGjwfVZUSU6JRWK=
NTERA-S-cl-D1 M3;FWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV2wWVdUUUN3ME2wMlAxOjB7IN88US=> NF7qRZBUSU6JRWK=
MFH-ino M1f5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHGUWhlUUN3ME2wMlAxOjZ6IN88US=> NH\FUnhUSU6JRWK=
IA-LM MlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq5UVVKSzVyPUCuNFAzQCEQvF2= Mmr6V2FPT0WU
MC116 NVjKTJlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMECyPFkh|ryP MWPTRW5ITVJ?
RKO MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3ITWM2OD1yLkCwNlk5KM7:TR?= NXjSUYhUW0GQR1XS
MRK-nu-1 MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\5NmlEPTB;MD6wNFI6QSEQvF2= NYjQV4VNW0GQR1XS
VA-ES-BJ MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXlTWM2OD1yLkCwN{DPxE1? NXjXVW9yW0GQR1XS
KALS-1 M3vER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTBNJVnUUN3ME2wMlAxOzB6IN88US=> NFTKWFZUSU6JRWK=
BB30-HNC MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\lU2lEPTB;MD6wNFMyPCEQvF2= MXzTRW5ITVJ?
ACN MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPseVBKSzVyPUCuNFA{OTZizszN NXWyb2IxW0GQR1XS
TE-9 NIjlfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml6wTWM2OD1yLkCwN|I3KM7:TR?= MkDBV2FPT0WU
SIG-M5 M3\nVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTrTWM2OD1yLkCwN|I4KM7:TR?= MlXnV2FPT0WU
no-10 NXPFcHF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwMECzOlIh|ryP M1;HWnNCVkeHUh?=
EW-1 MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknLTWM2OD1yLkCwN|cyKM7:TR?= MV3TRW5ITVJ?
SK-LMS-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fy[WlEPTB;MD6wNFQxOSEQvF2= M{DwS3NCVkeHUh?=
GT3TKB NYHhTFZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf5SpJYUUN3ME2wMlAxPDN2IN88US=> MWfTRW5ITVJ?
ES4 MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDDVFVKSzVyPUCuNFA1PDlizszN M130e3NCVkeHUh?=
IMR-5 NFTuNYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TKU2lEPTB;MD6wNFQ2KM7:TR?= NHHWdpNUSU6JRWK=
NCI-H1648 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDlZ3dkUUN3ME2wMlAxPDZ7IN88US=> M2iwc3NCVkeHUh?=
MV-4-11 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHe4SnZKSzVyPUCuNFA1PzVizszN MUfTRW5ITVJ?
SK-UT-1 NIXEfVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMEC0PEDPxE1? M2j0fXNCVkeHUh?=
NB13 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfL[ZBpUUN3ME2wMlAxPDlzIN88US=> NY\QN5lzW0GQR1XS
DJM-1 NGTRWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXYV41KSzVyPUCuNFA2OyEQvF2= Mmq0V2FPT0WU
ES8 Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7udXVKSzVyPUCuNFA2OzhizszN NE\MXWNUSU6JRWK=
TE-6 NH7XV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMEC1O{DPxE1? M1T0dHNCVkeHUh?=
KS-1 MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH3VolHUUN3ME2wMlAxPTh{IN88US=> M{K0[XNCVkeHUh?=
TE-1 NX7kUndRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\zSVRGUUN3ME2wMlAxPjB4IN88US=> MYfTRW5ITVJ?
ATN-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMEC2NFkh|ryP M37XOnNCVkeHUh?=
A4-Fuk Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH2x[nBKSzVyPUCuNFA3OTFizszN NXTlPVA3W0GQR1XS
ALL-PO NELHUnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn64TWM2OD1yLkCwOlMh|ryP NYPwOYp5W0GQR1XS
BE-13 MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fyWWlEPTB;MD6wNFY{PiEQvF2= MmfOV2FPT0WU
KM12 M4rXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXMR4VYUUN3ME2wMlAxPjN5IN88US=> NE\jOG1USU6JRWK=
NOS-1 NEPmU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn5dnZMUUN3ME2wMlAxPjVizszN NXjtd5RNW0GQR1XS
SW962 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\jT2lEPTB;MD6wNFY3OiEQvF2= MXTTRW5ITVJ?
OCUB-M MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDISplxUUN3ME2wMlAxPjZ{IN88US=> NYWyT2VbW0GQR1XS
NCI-H510A MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULGNGFEUUN3ME2wMlAxPjZ3IN88US=> NGnhb4dUSU6JRWK=
EW-16 M2fLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTwTWM2OD1yLkCwOlk1KM7:TR?= NWHDXIxlW0GQR1XS
KGN MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLn[3pvUUN3ME2wMlAxPzF{IN88US=> MnjIV2FPT0WU
LS-411N M3XQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTBN2ZDUUN3ME2wMlAxPzF5IN88US=> MnLvV2FPT0WU
Becker NEHQPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPqUotYUUN3ME2wMlAxPzJizszN NGrsdFRUSU6JRWK=
HC-1 NGfxOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMEC3NlEh|ryP MVfTRW5ITVJ?
CESS MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnsVndwUUN3ME2wMlAxPzN5IN88US=> NILhVVRUSU6JRWK=
KURAMOCHI NFGzR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMEC3OFgh|ryP MV;TRW5ITVJ?
TGBC24TKB M3vZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMEC3OVIh|ryP M3X2fHNCVkeHUh?=
SW982 NVHNSVVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NES5e5VKSzVyPUCuNFA4PjZizszN NFrxTXFUSU6JRWK=
HCE-4 M2HiWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMEC3Olch|ryP MmPMV2FPT0WU
LOUCY M1P5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e2c2lEPTB;MD6wNFc4PSEQvF2= M37lNnNCVkeHUh?=
8-MG-BA MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnGbldKSzVyPUCuNFA4QTZizszN MXHTRW5ITVJ?
HT-144 NITXW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rCeGlEPTB;MD6wNFgh|ryP M2TZN3NCVkeHUh?=
LXF-289 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TRXWlEPTB;MD6wNFgyQCEQvF2= NFzRPFlUSU6JRWK=
RS4-11 M1G0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjpdlJKSzVyPUCuNFA5OzZizszN MoL4V2FPT0WU
DEL MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDqTWM2OD1yLkCwPFQ2KM7:TR?= NH3iN2tUSU6JRWK=
OCI-AML2 MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;PUm9bUUN3ME2wMlAxQDV{IN88US=> NEG1T2lUSU6JRWK=
CCRF-CEM MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M334ZWlEPTB;MD6wNFg4OSEQvF2= NEfS[VZUSU6JRWK=
A388 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTQToFKSzVyPUCuNFA5PzRizszN MWrTRW5ITVJ?
KNS-42 NHfPNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\tV2lEPTB;MD6wNFg6OSEQvF2= NIHEfohUSU6JRWK=
OVCAR-4 NXn1WFJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;aZoZyUUN3ME2wMlAxQTB2IN88US=> MljHV2FPT0WU
NCI-H1355 NInrcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDKTWM2OD1yLkCwPVE1KM7:TR?= NHW1VIhUSU6JRWK=
BL-70 M3XtN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfCUodKSzVyPUCuNFA6OyEQvF2= MnO0V2FPT0WU
BL-41 NV74OY85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7lTWM2OD1yLkCwPVM1KM7:TR?= M2rwdnNCVkeHUh?=
A101D MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PLXGlEPTB;MD6wNFk3KM7:TR?= MmPrV2FPT0WU
HL-60 NFHrWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD6TWM2OD1yLkCwPVY3KM7:TR?= NGPnemhUSU6JRWK=
COR-L279 Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMEC5PVkh|ryP NGn4cWlUSU6JRWK=
NCI-SNU-16 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj1fIxTUUN3ME2wMlAyODB6IN88US=> MXfTRW5ITVJ?
Calu-6 NHHxPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrUTWM2OD1yLkCxNFEzKM7:TR?= NF\KOVdUSU6JRWK=
SR MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWCyXYF5UUN3ME2wMlAyODJ4IN88US=> MYHTRW5ITVJ?
QIMR-WIL NF\Xb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMEGwN|Mh|ryP M1TQR3NCVkeHUh?=
LB647-SCLC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMEGwOVEh|ryP NWX6PJdbW0GQR1XS
RPMI-8226 M1nY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\HWVRoUUN3ME2wMlAyOTB{IN88US=> NHLwV5lUSU6JRWK=
SK-PN-DW M3rTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvlTWM2OD1yLkCxNVEzKM7:TR?= M3H3eHNCVkeHUh?=
SF268 NH7WTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH76VJRKSzVyPUCuNFEyPTFizszN M1nV[3NCVkeHUh?=
HD-MY-Z M2DoSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPkRZNKSzVyPUCuNFEyPjNizszN Mmj5V2FPT0WU
DOHH-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DOTGlEPTB;MD6wNVIxOyEQvF2= M3H2XnNCVkeHUh?=
SCC-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMEGyNFQh|ryP NHztVVVUSU6JRWK=
ST486 Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjubYNEUUN3ME2wMlAyOjB2IN88US=> NHTKc29USU6JRWK=
NALM-6 NVrmNYtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXLTWM2OD1yLkCxNlE1KM7:TR?= MULTRW5ITVJ?
NCI-H1436 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDXTWM2OD1yLkCxNlMyKM7:TR?= M{XhXHNCVkeHUh?=
KE-37 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTITWM2OD1yLkCxNlM1KM7:TR?= MmfxV2FPT0WU
RPMI-8402 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XpRmlEPTB;MD6wNVI2PiEQvF2= MVTTRW5ITVJ?
RXF393 NXnr[oR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG3TWM2OD1yLkCxNlU4KM7:TR?= MWDTRW5ITVJ?
KARPAS-45 M17NOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXESnpqUUN3ME2wMlAyOjdizszN MVjTRW5ITVJ?
HOP-62 NWHVUoE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjCRm9KSzVyPUCuNFEzPzZizszN MVvTRW5ITVJ?
ES1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\3Z5lKSzVyPUCuNFEzQDhizszN MlvYV2FPT0WU
L-363 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3KOVFiUUN3ME2wMlAyOzVzIN88US=> NWfxRnhUW0GQR1XS
GI-1 NILMS|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXNdYVKSzVyPUCuNFE{PzNizszN MmHHV2FPT0WU
CTV-1 MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLJSFlYUUN3ME2wMlAyPDd6IN88US=> NGfXb2JUSU6JRWK=
TE-5 NFPFOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofmTWM2OD1yLkCxOFk3KM7:TR?= Mo\aV2FPT0WU
SNU-C2B MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMEG0PVYh|ryP MVfTRW5ITVJ?
K-562 Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XtZmlEPTB;MD6wNVUyPiEQvF2= MmrSV2FPT0WU
SNB75 NYm4dFJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LqPWlEPTB;MD6wNVU1KM7:TR?= NHXlWHdUSU6JRWK=
MOLT-13 NHnjTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXWTWM2OD1yLkCxOlM4KM7:TR?= M2n1XnNCVkeHUh?=
LS-123 NYHBbWV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrFVY1{UUN3ME2wMlAyPjZ2IN88US=> NHX2b5lUSU6JRWK=
NCI-SNU-5 NV;WSZA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr5TWM2OD1yLkCxO|AyKM7:TR?= NU\N[ll3W0GQR1XS
Daudi MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn5UXNHUUN3ME2wMlAyPzB6IN88US=> MVfTRW5ITVJ?
A253 M1rXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP1TWM2OD1yLkCxO|M5KM7:TR?= NH3R[WpUSU6JRWK=
TGBC1TKB NFy4SY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXKenVKSzVyPUCuNFE4PTJizszN MmHIV2FPT0WU
SJSA-1 NYfiR4Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEG3Olch|ryP MorNV2FPT0WU
NCCIT NFnCSHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1yxcWlEPTB;MD6wNVc3QSEQvF2= MUnTRW5ITVJ?
NCI-H69 MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXLW25KSzVyPUCuNFE4PzhizszN NH3Nc5BUSU6JRWK=
SH-4 NHXHPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[5TWM2OD1yLkCxPFk2KM7:TR?= M1PNUHNCVkeHUh?=
HCC1187 NXe5fppMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMEG5NlQh|ryP MnzKV2FPT0WU
HCC1599 NX[wdYx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf1cnpKSzVyPUCuNFIxOiEQvF2= MojEV2FPT0WU
ONS-76 NVPWfFU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMEKwN|Yh|ryP MUPTRW5ITVJ?
KU812 NUK2SGJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFKwXFVKSzVyPUCuNFIxOzlizszN NVTwTmt7W0GQR1XS
ML-2 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkSwTWM2OD1yLkCyNFQ4KM7:TR?= NHHDUJFUSU6JRWK=
HCE-T NUPuTZA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG2TFhKSzVyPUCuNFIxQTJizszN MYjTRW5ITVJ?
NCI-H446 MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PHemlEPTB;MD6wNlEyOiEQvF2= MX;TRW5ITVJ?
RPMI-6666 MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMEKxOFkh|ryP NUWwO2d1W0GQR1XS
MOLT-16 NX\3bnlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjySll1UUN3ME2wMlAzOTV|IN88US=> M3TSUXNCVkeHUh?=
JiyoyeP-2003 M3XSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fVXmlEPTB;MD6wNlE4PiEQvF2= MWnTRW5ITVJ?
MHH-PREB-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTjTWM2OD1yLkCyNVkyKM7:TR?= M{G4RXNCVkeHUh?=
MC-CAR NU\4NWlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnhWJk4UUN3ME2wMlAzOzJ4IN88US=> M4TCU3NCVkeHUh?=
BC-3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm5TWM2OD1yLkCyN|Q1KM7:TR?= MkT6V2FPT0WU
KINGS-1 NHPvWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7qTWM2OD1yLkCyN|U2KM7:TR?= M1PucHNCVkeHUh?=
PF-382 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TE[2lEPTB;MD6wNlM4QCEQvF2= Ml:yV2FPT0WU
J-RT3-T3-5 NGe5TohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHOwS|NKSzVyPUCuNFI{QDNizszN M2\K[3NCVkeHUh?=
SF539 NIHuS2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor1TWM2OD1yLkCyOFAyKM7:TR?= M{PFZXNCVkeHUh?=
LB831-BLC M3zSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmCyTWM2OD1yLkCyOFg2KM7:TR?= NWXaNoRIW0GQR1XS
DMS-114 Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DmTWlEPTB;MD6wNlUxOiEQvF2= M1rF[3NCVkeHUh?=
LB1047-RCC M{LTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMEK1NUDPxE1? NVW3eGZ[W0GQR1XS
LB771-HNC Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMEK1N|Qh|ryP MlnTV2FPT0WU
BB65-RCC M{OybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjGN3ZtUUN3ME2wMlAzPTN2IN88US=> MV;TRW5ITVJ?
BV-173 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nvUWlEPTB;MD6wNlU2PCEQvF2= MULTRW5ITVJ?
ARH-77 Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTscZVuUUN3ME2wMlAzPjBzIN88US=> MUDTRW5ITVJ?
IST-MEL1 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnHTWM2OD1yLkCyOlI{KM7:TR?= NYjZWItNW0GQR1XS
NB1 NGK2S3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm0cYJQUUN3ME2wMlAzPjh5IN88US=> MWDTRW5ITVJ?
EoL-1-cell MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMEK2PFgh|ryP NYfGSXJ4W0GQR1XS
KY821 NILYNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LrWmlEPTB;MD6wNlY6PyEQvF2= M2DubXNCVkeHUh?=
CMK MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7uTWM2OD1yLkCyO|M1KM7:TR?= NUfqTYlTW0GQR1XS
NCI-H2126 Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMEK3Olgh|ryP M1;FUXNCVkeHUh?=
NCI-H526 MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn5NmtDUUN3ME2wMlAzQDlzIN88US=> MX;TRW5ITVJ?
COLO-684 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDjVHJjUUN3ME2wMlAzQTB6IN88US=> NGjXRVRUSU6JRWK=
NCI-H747 NITkZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfCeY5KSzVyPUCuNFI6OzNizszN NUDXU2lJW0GQR1XS
JAR MoKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TwO2lEPTB;MD6wNlk1PiEQvF2= NV\mRmREW0GQR1XS
MEG-01 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3J[nZKSzVyPUCuNFI6PzhizszN MXfTRW5ITVJ?
MONO-MAC-6 NXT5N5h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEOwNlMh|ryP NEfVXnNUSU6JRWK=
IST-SL1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLJTWM2OD1yLkCzNFQzKM7:TR?= MnrOV2FPT0WU
CPC-N Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXqO3J5UUN3ME2wMlA{ODd7IN88US=> MlLFV2FPT0WU
NCI-H1963 M{DCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUS0[XNQUUN3ME2wMlA{OTNzIN88US=> NFfmUZFUSU6JRWK=
K052 M{HNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\NO4JKSzVyPUCuNFMzPDdizszN NEe1fFNUSU6JRWK=
KM-H2 NGjjRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPyTWM2OD1yLkCzN|A4KM7:TR?= M{nqPXNCVkeHUh?=
TE-12 NFjoZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3HbYN6UUN3ME2wMlA{OzB7IN88US=> M3vGfXNCVkeHUh?=
TK10 MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[3TWM2OD1yLkCzN|U3KM7:TR?= M1;0ZnNCVkeHUh?=
NMC-G1 MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTCeVlKSzVyPUCuNFM1PTJizszN NYHNdIQxW0GQR1XS
no-11 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnxfWlNUUN3ME2wMlA{PDd6IN88US=> MVHTRW5ITVJ?
NCI-H524 MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m1OmlEPTB;MD6wN|UzQSEQvF2= NV7GVVh[W0GQR1XS
MHH-CALL-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInSbWVKSzVyPUCuNFM2PjJizszN NVHlTYFCW0GQR1XS
GB-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XJcWlEPTB;MD6wN|Yh|ryP Mo\2V2FPT0WU
OPM-2 NHXIdnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPSUJR2UUN3ME2wMlA{Pjd|IN88US=> NE\xNZlUSU6JRWK=
RH-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nzbmlEPTB;MD6wN|gyQSEQvF2= NVO1ToVuW0GQR1XS
NCI-H64 M3:0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMEO4OVch|ryP M37vOXNCVkeHUh?=
EVSA-T M37rTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3TeWhGUUN3ME2wMlA{QTJ|IN88US=> NFvUeG9USU6JRWK=
KARPAS-299 M{D5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMEO5PEDPxE1? NGfPN5pUSU6JRWK=
MZ7-mel M3\yXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMESwOEDPxE1? M1\RZnNCVkeHUh?=
LB373-MEL-D MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4CyU2lEPTB;MD6wOFExPSEQvF2= NVjYWoxKW0GQR1XS
HEL MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\KTWM2OD1yLkC0NVQh|ryP MonJV2FPT0WU
SW872 NUn0Z2d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PMb2lEPTB;MD6wOFIyKM7:TR?= NFvLRZVUSU6JRWK=
DU-4475 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LPVGlEPTB;MD6wOFI1PCEQvF2= NYnpeHVJW0GQR1XS
IST-SL2 NYf0TJdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfjTWM2OD1yLkC0Nlc2KM7:TR?= M1\FOnNCVkeHUh?=
NCI-H82 M4XQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\DcWlEPTB;MD6wOFMxPyEQvF2= NIDGdGFUSU6JRWK=
LC4-1 M1v5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2CxR2lEPTB;MD6wOFM2OSEQvF2= MV3TRW5ITVJ?
HDLM-2 NX7EdIZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMESzPVIh|ryP MXXTRW5ITVJ?
MMAC-SF M3f3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmezTWM2OD1yLkC0OVM1KM7:TR?= M2DxdnNCVkeHUh?=
L-540 M2XRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMES2N|kh|ryP MoT3V2FPT0WU
MZ2-MEL NHvqUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnUTWM2OD1yLkC0O|QzKM7:TR?= M2\TZnNCVkeHUh?=
LU-134-A NWXJ[odvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMES3O|Mh|ryP NWfLT2FFW0GQR1XS
UACC-257 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwMES4OFkh|ryP MWfTRW5ITVJ?
NCI-H1581 MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMES5OVMh|ryP Mkn2V2FPT0WU
NB17 M1jPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4izcWlEPTB;MD6wOFk4QSEQvF2= MmHBV2FPT0WU
SBC-1 NXewcYw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jHTWlEPTB;MD6wOVA1OiEQvF2= MV\TRW5ITVJ?
TALL-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofPTWM2OD1yLkC1NFQ2KM7:TR?= NVHGdnc6W0GQR1XS
NCI-H1304 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO1XndKSzVyPUCuNFUzODhizszN MWPTRW5ITVJ?
NEC8 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfUeZpWUUN3ME2wMlA2Ojh4IN88US=> MUTTRW5ITVJ?
CAL-148 M2L1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMEW0N|kh|ryP Mnq0V2FPT0WU
CGTH-W-1 NYT1V4g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTtSpd5UUN3ME2wMlA2PDR7IN88US=> M1q5fHNCVkeHUh?=
NCI-H889 NGnOWXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMEW1PVIh|ryP NVTwfndqW0GQR1XS
GR-ST NVXIR|VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXVcGNKSzVyPUCuNFU3OjFizszN MUXTRW5ITVJ?
KARPAS-422 M3Syfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW2PHppUUN3ME2wMlA2PjVizszN NIfpXphUSU6JRWK=
RPMI-8866 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEW3NVIh|ryP M3nHeXNCVkeHUh?=
SCLC-21H M4i1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjsWYpKSzVyPUCuNFU5QDRizszN NFHlTpdUSU6JRWK=
COR-L88 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K1XWlEPTB;MD6wOVkzPyEQvF2= Ml;LV2FPT0WU
LU-139 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D4WWlEPTB;MD6wOVk5PiEQvF2= Mnz0V2FPT0WU
SF126 MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXT[5VKSzVyPUCuNFYyOzNizszN MYLTRW5ITVJ?
NCI-H1882 NHPCd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrJfY5JUUN3ME2wMlA3PDJ2IN88US=> MkX5V2FPT0WU
EW-24 NWe0UZhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;hc2NpUUN3ME2wMlA3PDh|IN88US=> NILzdXpUSU6JRWK=
CP67-MEL NVztUmJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwME[4NUDPxE1? NV;P[XR4W0GQR1XS
DG-75 Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwME[4PVkh|ryP NUC1NYs6W0GQR1XS
LOXIMVI NIHQZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMEewNlgh|ryP MmnVV2FPT0WU
HH MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMEexOVch|ryP MXrTRW5ITVJ?
K5 NH\MfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\ZOGlEPTB;MD6wO|IzPiEQvF2= M2SyUXNCVkeHUh?=
EC-GI-10 NY\hN2RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjXPXRKSzVyPUCuNFczPTdizszN Mmm2V2FPT0WU
SK-N-DZ Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMEezNFch|ryP MYPTRW5ITVJ?
A3-KAW MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHrTWM2OD1yLkC3N|UyKM7:TR?= MVTTRW5ITVJ?
MLMA MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzmTWM2OD1yLkC3OFY2KM7:TR?= MlntV2FPT0WU
LB996-RCC M1Xhe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMEe3NFch|ryP MWjTRW5ITVJ?
OS-RC-2 MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;IPIg1UUN3ME2wMlA4PzR6IN88US=> M1zVR3NCVkeHUh?=
CTB-1 NXW3ZXJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;IbmlEPTB;MD6wO|gyKM7:TR?= NHuzNYJUSU6JRWK=
IST-MES1 NV\1SGxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPETWM2OD1yLkC3PVEzKM7:TR?= Mnf6V2FPT0WU
LS-1034 MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMEiwN|Uh|ryP NULCTFA4W0GQR1XS
HT M{jvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4SxbWlEPTB;MD6wPFA5PiEQvF2= M{TpNHNCVkeHUh?=
NCI-H2141 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPE[4dGUUN3ME2wMlA5OSEQvF2= NFLFdHZUSU6JRWK=
LB2518-MEL MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG0TWM2OD1yLkC4NVQyKM7:TR?= NWHLSHV6W0GQR1XS
GI-ME-N NFXmfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M376dmlEPTB;MD6wPFQ2OiEQvF2= NF\UTY5USU6JRWK=
TGW NHroRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMEi2NFch|ryP MXjTRW5ITVJ?
SK-NEP-1 NHzQNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvWbpBMUUN3ME2wMlA5PjRzIN88US=> MXfTRW5ITVJ?
NOMO-1 Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnITot6UUN3ME2wMlA6Ojd3IN88US=> MYHTRW5ITVJ?
ES6 MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUG4UHRXUUN3ME2wMlA6PTh7IN88US=> MnjwV2FPT0WU
NCI-H209 MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHhTWM2OD1yLkC5O|g3KM7:TR?= NXXQRnlZW0GQR1XS
GAK M3HybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMUCxOkDPxE1? NV7nRlY2W0GQR1XS
BC-1 MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPPS3RKSzVyPUCuNVA{PjFizszN M2XwbnNCVkeHUh?=
KLE NInYfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHlRpJKSzVyPUCuNVA1PDNizszN M3v1UnNCVkeHUh?=
EW-3 Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnYSZJMUUN3ME2wMlExQThizszN NHT2VGdUSU6JRWK=
NKM-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTVeW5KSzVyPUCuNVEyKM7:TR?= NIjBOVFUSU6JRWK=
D-336MG M2S2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHlTWM2OD1yLkGxNlQ1KM7:TR?= Mm\WV2FPT0WU
NB69 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvCcXNyUUN3ME2wMlEyOzBzIN88US=> NHfxOWVUSU6JRWK=
D-263MG NVP0UXBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMUG3NVIh|ryP MVPTRW5ITVJ?
KP-N-YS Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPwTWM2OD1yLkGyNlkyKM7:TR?= MXrTRW5ITVJ?
NCI-H1155 NFS1SJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT2R5Y2UUN3ME2wMlEzPTV6IN88US=> MULTRW5ITVJ?
BOKU NELhV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LHO2lEPTB;MD6xNlU4QSEQvF2= NX\ZemJ[W0GQR1XS
LAMA-84 NXXxRVd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7zTWM2OD1yLkGyPVkh|ryP M4jnOXNCVkeHUh?=
Raji NEmxNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMUOxNVch|ryP MUPTRW5ITVJ?
LU-65 NI\Q[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnLc5kzUUN3ME2wMlE{OzB5IN88US=> NIDUPZlUSU6JRWK=
NCI-H187 MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjkW5A{UUN3ME2wMlE{QTJ2IN88US=> NUXrd4hCW0GQR1XS
GCIY NV:0O|g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XmNWlEPTB;MD6xOFkxOSEQvF2= NFW1dZdUSU6JRWK=
NCI-H2107 NEnjNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMUWwPEDPxE1? MUXTRW5ITVJ?
NCI-H1522 M4rjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMUWyOlYh|ryP M2GzcHNCVkeHUh?=
NB6 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnHUnBKSzVyPUCuNVU3OjNizszN NGPQeJVUSU6JRWK=
EM-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwMUW3NFYh|ryP NWDuU25EW0GQR1XS
HCC2218 M1;ZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PO[WlEPTB;MD6xOVk5KM7:TR?= MmO4V2FPT0WU
NCI-H748 NV\pdG5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\xTWM2OD1yLkG2N|c3KM7:TR?= NVLINIF7W0GQR1XS
MS-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMU[1N|ch|ryP M3vkd3NCVkeHUh?=
NB5 MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTVN2Y4UUN3ME2wMlE3PTl5IN88US=> MnzHV2FPT0WU
OMC-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMU[2PFgh|ryP MonUV2FPT0WU
NCI-H345 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnMSnZKSzVyPUCuNVY6OjhizszN NEm2S2xUSU6JRWK=
L-428 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMU[5OFUh|ryP M3H1dXNCVkeHUh?=
SCH M163Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPkTWM2OD1yLkG4Olg2KM7:TR?= MkDRV2FPT0WU
NCI-H1417 NXzZSpJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3XWINKSzVyPUCuNVkzOjdizszN NUPSXmg5W0GQR1XS
COLO-320-HSR NUPQSoc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInicnNKSzVyPUCuNVk2OzJizszN NG\3WmlUSU6JRWK=
BT-474 NV3RNY1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rNVWlEPTB;MD6yNFg6OiEQvF2= NETmPWJUSU6JRWK=
GDM-1 M{nMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7OOVIxUUN3ME2wMlIyQTdzIN88US=> M{jOTnNCVkeHUh?=
NCI-H2196 NWHVfmgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEGyZlVKSzVyPUCuNlIzOzVizszN NV\NWJVKW0GQR1XS
KP-N-RT-BM-1 M2PMPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr0dHNKSzVyPUCuNlI{PDlizszN MVzTRW5ITVJ?
KNS-81-FD MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMkK5OVgh|ryP NUDSVWM5W0GQR1XS
COLO-668 NF3iPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMkO2O|Uh|ryP M4\DS3NCVkeHUh?=
C2BBe1 M2ezVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnK5TWM2OD1yLkK2O|Q4KM7:TR?= NILmNWxUSU6JRWK=
Ramos-2G6-4C10 NWn0UmpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMk[5OVQh|ryP MYHTRW5ITVJ?
CAS-1 NHrISpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFS0b5NKSzVyPUCuNlcxQTZizszN M3vuZXNCVkeHUh?=
GOTO MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\ZTWM2OD1yLkK3PFk1KM7:TR?= MVXTRW5ITVJ?
LP-1 NGjNNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMkiwOVch|ryP MYLTRW5ITVJ?
NCI-SNU-1 NH[3N2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3LTWM2OD1yLkK5OFIzKM7:TR?= M2CyeXNCVkeHUh?=
EB-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP1OVVKSzVyPUCuNlk6PzlizszN M3nP[HNCVkeHUh?=
MHH-NB-11 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L4e2lEPTB;MD6zNFQxOiEQvF2= Mo\OV2FPT0WU
SK-N-FI Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwM{G2PVIh|ryP NGH6[4lUSU6JRWK=
HCC2157 NH;lZVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwM{O5NVMh|ryP NXq2bGJZW0GQR1XS
SIMA MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHBclFXUUN3ME2wMlM1PThzIN88US=> NUnDbJRtW0GQR1XS
MDA-MB-134-VI M2LqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojkTWM2OD1yLkO2PVI5KM7:TR?= Mlu2V2FPT0WU
NCI-H1694 NFnlR29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPrNpdKSzVyPUCuN|ch|ryP NEjxd21USU6JRWK=
EHEB MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVqwd2MyUUN3ME2wMlM6ODh3IN88US=> NXThSVB7W0GQR1XS
U-266 MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nyfWlEPTB;MD6zPVg1PiEQvF2= NHz2VZJUSU6JRWK=
LC-1F M3nnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;JUXliUUN3ME2wMlQ{PzZ3IN88US=> NXnFR204W0GQR1XS
SHP-77 NWWxeGhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W1UWlEPTB;MD60O|g2PSEQvF2= NUnG[nZiW0GQR1XS
LS-513 NYPYeXo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwNEmzNFch|ryP NYf6eoU6W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]
臨床試験 Paclitaxel has entered in a Phase III clinical trial for the treatment of tubular breast cancer stage II, mucinous breast cancer stage II, breast cancer female NOS and invasive ductal breast cancer.
特集

プロトコル (参考用のみ)

細胞アッセイ: [1]

細胞株 Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
濃度 0.1-100 pM
反応時間 72 hours
実験の流れ Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

動物実験: [4]

動物モデル Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
製剤 Control
投薬量 20 mg/kg
投与方法 Administered via i.v.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Paclitaxel SDF
分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管 2年-20℃
6月-80℃in solvent
別名 NSC 125973
溶解度 (25°C) * In vitro DMSO 171 mg/mL (200.25 mM)
エタノール 18 mg/mL (21.07 mM)
<1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-

カスタマーフィードバック (2)


Click to enlarge
Rating
Source , , ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck
Method Confocal Laser Scanning Microscopy Study
Cell Lines HeLa cells
Concentrations 5 μM
Incubation Time 24 h
Results From the figure, it was clear that interestingly α-TOS-Paclitaxel-NP induced highest PARP expression compared to α-TOS-CDDP-NP and α-TOS-Dox-NP.

Click to enlarge
Rating
Source RSC Adv , 2011, 1, 884-892. Paclitaxel purchased from Selleck
Method Microscope image
Cell Lines U937 cells
Concentrations
Incubation Time 24 h
Results The ODS-treated cells in Fig. b looked identical to the untreated cells in Fig. a with a similar rate of natural cell death of less than 3%. When Taxol microcrystals are added to the cell culture (the standard way that Taxol is released into biological systems), decreased cell proliferation rate, pronounced swelling and vacuolization are observed, as shown in Fig. c.

文献中の引用 (16)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related 微小管関連 阻害剤

  • TAI-1

    TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.

  • Docetaxel Trihydrate

    Docetaxel, an analog of taxol, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Combretastatin A4

    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

  • FRAX597

    FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.

  • Docetaxel

    Docetaxel is an microtubule disassembly inhibitor with IC50 of a range of 0.31-100 ηM.

  • Vincristine sulfate

    Vincristine is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM.

  • Nocodazole

    Nocodazoleは反微小管薬品で、 ABL、 ABL(E255K) 、ABL(T315I)に作用すると 、 IC50 が それぞれ0.21 μM、 0.53 μM 、 0.64 μMになる。

  • Vinblastine

    Vinblastine inhibits microtubule formation and supresses nAChR activity with IC50 of 8.9 μM.

  • Vinorelbine Tartrate

    Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

最近チェックしたアイテム

Tags: Paclitaxelを買う | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ